BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25093289)

  • 1. Development and internal validation of a prognostic model for survival after debulking surgery for epithelial ovarian cancer.
    Rutten MJ; Boldingh JH; Schuit E; Trum H; van Driel W; Mol BW; Kenter GG; Buist MR
    Gynecol Oncol; 2014 Oct; 135(1):13-8. PubMed ID: 25093289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer.
    Barlin JN; Yu C; Hill EK; Zivanovic O; Kolev V; Levine DA; Sonoda Y; Abu-Rustum NR; Huh J; Barakat RR; Kattan MW; Chi DS
    Gynecol Oncol; 2012 Apr; 125(1):25-30. PubMed ID: 22155261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer.
    Xu XL; Cheng H; Tang MS; Zhang HL; Wu RY; Yu Y; Li X; Wang XM; Mai J; Yang CL; Jiao L; Li ZL; Zhong ZM; Deng R; Li JD; Zhu XF
    Oncotarget; 2017 Jan; 8(5):8120-8130. PubMed ID: 28042955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
    Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
    Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV.
    Ataseven B; Grimm C; Harter P; Heitz F; Traut A; Prader S; du Bois A
    Gynecol Oncol; 2016 Feb; 140(2):215-20. PubMed ID: 26691222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?
    Lydiksen L; Jensen-Fangel S; Blaakaer J
    Gynecol Oncol; 2014 Jun; 133(3):454-9. PubMed ID: 24726613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting non-home discharge in epithelial ovarian cancer patients: External validation of a predictive model.
    Connor EV; Newlin EM; Jelovsek JE; AlHilli MM
    Gynecol Oncol; 2018 Oct; 151(1):129-133. PubMed ID: 30107886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
    van Vliet MM; Schreuder HW; Pasker-de Jong PC; Duk MJ
    Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():72-8. PubMed ID: 26177496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
    Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
    Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma.
    Chi DS; Palayekar MJ; Sonoda Y; Abu-Rustum NR; Awtrey CS; Huh J; Eisenhauer EL; Barakat RR; Kattan MW
    Gynecol Oncol; 2008 Jan; 108(1):191-4. PubMed ID: 17950784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic.
    Wahner Hendrickson AE; Hawthorne KM; Goode EL; Kalli KR; Goergen KM; Bakkum-Gamez JN; Cliby WA; Keeney GL; Visscher DW; Tarabishy Y; Oberg AL; Hartmann LC; Maurer MJ
    Gynecol Oncol; 2015 Apr; 137(1):77-85. PubMed ID: 25620544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Pérez-Milán F; Ortiz-Quintana L
    Surg Oncol; 2014 Mar; 23(1):40-4. PubMed ID: 24183480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
    Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
    Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
    Kumar A; Janco JM; Mariani A; Bakkum-Gamez JN; Langstraat CL; Weaver AL; McGree ME; Cliby WA
    Gynecol Oncol; 2016 Jan; 140(1):15-21. PubMed ID: 26541980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peri-operative allogeneic blood transfusion is associated with poor overall survival in advanced epithelial ovarian Cancer; potential impact of patient blood management on Cancer outcomes.
    Connor JP; O'Shea A; McCool K; Sampene E; Barroilhet LM
    Gynecol Oncol; 2018 Nov; 151(2):294-298. PubMed ID: 30201233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery.
    Paulsen T; Kærn J; Tropé C
    Gynecol Oncol; 2011 Jul; 122(1):83-8. PubMed ID: 21435701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study.
    Anuradha S; Donovan PJ; Webb PM; Brand AH; Goh J; Friedlander M; Oehler MK; Quinn M; Steer C; Jordan SJ
    Acta Oncol; 2016; 55(2):226-33. PubMed ID: 26079434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.